View Older Stories View More Recent Stories

Sep 28, 2021 09:20AM Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
Sep 22, 2021 09:00AM Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference on September 29th
Sep 7, 2021 09:02AM Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September
Sep 2, 2021 08:59AM Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives
Aug 30, 2021 08:59AM Lantern Pharma (LTRN) Granted FDA Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas
Aug 30, 2021 08:59AM FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas
Aug 19, 2021 08:50AM Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
Aug 16, 2021 08:20AM Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
Aug 11, 2021 08:22AM Lantern Pharma (LTRN) Announces FDA Grants it Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Aug 11, 2021 08:21AM FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Jul 29, 2021 04:01PM Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Jul 27, 2021 08:06AM Lantern Pharma (LTRN) Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
Jul 27, 2021 08:00AM Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
Jul 22, 2021 04:08PM Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
Jul 20, 2021 07:08AM Lantern Pharma (LTRN) Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
Jul 20, 2021 07:00AM Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
May 3, 2021 04:32PM Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
May 3, 2021 07:10AM Lantern Pharma (LTRN), Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform
May 3, 2021 07:00AM Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform
Apr 29, 2021 07:00AM Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collab
Apr 26, 2021 04:30PM Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET
Apr 26, 2021 07:45AM Lantern Pharma (LTRN) Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget
Apr 26, 2021 07:45AM Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget
Apr 6, 2021 07:45AM Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference
Apr 1, 2021 07:59AM Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins
Mar 23, 2021 07:49AM Lantern Pharma (LTRN) to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
Mar 23, 2021 07:48AM Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
Mar 17, 2021 07:00AM Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties
Mar 12, 2021 09:00AM Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
Mar 10, 2021 04:00PM Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
Mar 3, 2021 07:00AM Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4:00 p.m. ET
Jan 20, 2021 04:00PM Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option
Jan 15, 2021 05:56AM Lantern Pharma (LTRN) Prices 4.28M Share IPO at $14/Sh
Jan 14, 2021 09:30PM Lantern Pharma Announces Pricing of $60 Million Public Offering
Jan 4, 2021 07:00AM Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma
Dec 17, 2020 07:00AM Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma
Dec 15, 2020 07:06AM Lantern Pharma (LTRN) Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
Dec 15, 2020 07:00AM Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
Nov 24, 2020 07:30AM Lantern Pharma Announces Upcoming Conference Presentations
Oct 29, 2020 03:59PM Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress
Oct 22, 2020 07:00AM Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET
Oct 5, 2020 07:59AM Lantern Pharma (LTRN) Reports Advancement of Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184
Oct 5, 2020 07:46AM Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent
Sep 22, 2020 07:56AM Lantern Pharma (LTRN) Announces Pact with Fox Chase Cancer Center Focused on Advancing Development of LP-184 in Pancreatic Cancer
Sep 22, 2020 07:55AM Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer
Aug 27, 2020 07:55AM Lantern Pharma Announces Upcoming Conference Presentations
Aug 14, 2020 02:25PM Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money Report
Jul 30, 2020 06:57AM Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
Jul 24, 2020 07:56AM Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020
Jun 29, 2020 08:45AM Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Da
View More Recent Stories View Older Stories